Pre-Eclampsia - Pipeline Review, H1 2016

Date: March 30, 2016
Pages: 64
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P29B2CE8EA8EN
Leaflet:

Download PDF Leaflet

Pre-Eclampsia - Pipeline Review, H1 2016

SUMMARY

Global Markets Direct’s, ‘Pre-Eclampsia - Pipeline Review, H1 2016’, provides an overview of the Pre-Eclampsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
  • The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects
  • The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Pre-Eclampsia Overview
Therapeutics Development
Pipeline Products for Pre-Eclampsia - Overview
Pre-Eclampsia - Therapeutics under Development by Companies
Pre-Eclampsia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Pre-Eclampsia - Products under Development by Companies
Pre-Eclampsia - Companies Involved in Therapeutics Development
A1M Pharma AB
Alnylam Pharmaceuticals, Inc.
Glenveigh Medical, LLC
Pluristem Therapeutics Inc.
rEVO Biologics, Inc.
RTI International
VG Life Sciences, Inc.
Pre-Eclampsia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A1M-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-AGT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
antithrombin alfa (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
digoxin immune fab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Apelin Receptor for Pre-Eclampsia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize CLR and RAMP Receptors for Pre-Eclampsia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VG-1177 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pre-Eclampsia - Recent Pipeline Updates
Pre-Eclampsia - Dormant Projects
Pre-Eclampsia - Product Development Milestones
Featured News & Press Releases
Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Preeclampsia
Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells
Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem’s PLX-PAD Cells for Treatment of Severe Preeclampsia
Sep 24, 2015: New clinical trial at SLU treats preeclampsia in second-trimester pregnancies
Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia
Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting
Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1)
Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma’s Treatment for Preeclampsia
Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia
Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Pre-Eclampsia, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Pre-Eclampsia - Pipeline by A1M Pharma AB, H1 2016
Pre-Eclampsia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
Pre-Eclampsia - Pipeline by Glenveigh Medical, LLC, H1 2016
Pre-Eclampsia - Pipeline by Pluristem Therapeutics Inc., H1 2016
Pre-Eclampsia - Pipeline by rEVO Biologics, Inc., H1 2016
Pre-Eclampsia - Pipeline by RTI International, H1 2016
Pre-Eclampsia - Pipeline by VG Life Sciences, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pre-Eclampsia Therapeutics - Recent Pipeline Updates, H1 2016
Pre-Eclampsia - Dormant Projects, H1 2016

LIST OF FIGURES

Number of Products under Development for Pre-Eclampsia, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

COMPANIES MENTIONED

A1M Pharma AB
Alnylam Pharmaceuticals, Inc.
Glenveigh Medical, LLC
Pluristem Therapeutics Inc.
rEVO Biologics, Inc.
RTI International
VG Life Sciences, Inc.
Skip to top


Pre-Eclampsia - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 63 pages
Pre-Eclampsia Global Clinical Trials Review, H1, 2016 US$ 2,125.00 Apr, 2016 · 129 pages
Orion Oyj - Product Pipeline Review - 2016 US$ 1,275.00 Mar, 2016 · 58 pages
Sanofi Pasteur SA - Product Pipeline Review - 2016 US$ 1,275.00 Mar, 2016 · 59 pages

Ask Your Question

Pre-Eclampsia - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: